Product pharmaceutical-intermediates-nuclide-drug

Home > products > pharmaceutical-intermediates> nuclide-drug

Catalog	name	Description	price
R-M2-9201	TLX591-CDx	The target of TLX591-CDx is PSMA, which can be used for imaging diagnosis of prostate cancer. Virtual price, please inquire if needed. We can mass produce (kg level),process scaling up, pilot supply,raw material supply, and intermediate production. Our production technology is mature and more cost-effective. Feel free to inquire at any time.	price>
R-M2-9202	68Ga-PSMA-11	68Ga-PSMA-11 is a radiopharmaceutical used in positron emission tomography (PET) imaging for detecting prostate cancer. This radiotracer targets prostate-specific membrane antigen (PSMA), a protein that is overexpressed in prostate cancer cells, allowing for highly specific imaging of prostate cancer. When injected into the body, the radioactive gallium-68 emits positrons that generate signals picked up by the PET scanner, providing highly detailed images of the distribution and concentration of PSMA in the body. This imaging helps in the initial staging, restaging, and monitozring of prostate cancer, and it can be useful in guiding treatment decisions. Virtual price, please inquire if needed. We can mass produce (kg level),process scaling up, pilot supply,raw material supply, and intermediate production. Our production technology is mature and more cost-effective. Feel free to inquire at any time.	price>
R-M2-9203	177Ga-PSMA-617/Pluvicto	177Ga-PSMA-617/Pluvicto is an emerging radiopharmaceutical used for targeted radioactive therapy of cancer.PSMA-617 is a small molecule that selectively binds to prostate-specific membrane antigen (PSMA), a protein highly expressed on prostate cancer cells. By combining this targeting molecule with Gallium-177, which emits beta particles, it is possible to deliver targeted radiation to prostate cancer cells. Virtual price, please inquire if needed. We can mass produce (kg level),process scaling up, pilot supply,raw material supply, and intermediate production. Our production technology is mature and more cost-effective. Feel free to inquire at any time.	price>
R-M2-9204	68Ga-Pentixafor	68Ga-Pentixafor is a radiopharmaceutical used in molecular imaging for visualizing the expression of the CXCR4 receptor, which is involved in various diseases, including cancer and inflammatory conditions. This radiotracer, labeled with gallium-68, is particularly useful in positron emission tomography (PET) imaging to locate and assess the expression of CXCR4. Virtual price, please inquire if needed. We can mass produce (kg level),process scaling up, pilot supply,raw material supply, and intermediate production. Our production technology is mature and more cost-effective. Feel free to inquire at any time.	price>
R-M2-9205	177Lu-Pentixather	177Lu-Pentixather is an emerging radiopharmaceutical used in targeted radionuclide therapy. Pentixather is a small molecule that selectively binds to the CXCR4 receptor. By combining this targeting molecule with Lutetium-177, which emits beta particles, it becomes possible to deliver targeted radiation to cells that overexpress the CXCR4 receptor. Virtual price, please inquire if needed. We can mass produce (kg level),process scaling up, pilot supply,raw material supply, and intermediate production. Our production technology is mature and more cost-effective. Feel free to inquire at any time.	price>
R-M2-9206	68Ga-FAPI-04	68Ga-FAPI-04 is a radiopharmaceutical used in positron emission tomography (PET) imaging for the visualization of fibroblast activation protein (FAP) in various cancers. FAP is found in the tumor stroma of many epithelial cancers, and its imaging with 68Ga-FAPI-04 can help in staging, restaging, and therapy response assessment. The tracer ability to target FAP allows for precise imaging of the tumor microenvironment, aiding in the characterization of tumors and potentially influencing treatment decisions. This development presents a significant advancement in the field of molecular imaging and targeted cancer diagnostics. Virtual price, please inquire if needed.We can mass produce (kg level),process scaling up, pilot supply,raw material supply, and intermediate production. Our production technology is mature and more cost-effective. Feel free to inquire at any time.	price>
R-M2-9207	177Lu-FAPI-46	177Lu-FAPI-46 refers to an investigational radiopharmaceutical designed for targeted radionuclide therapy in cancer.This therapy approach aims to deliver localized radiation to cancer cells by specifically targeting FAP-expressing cells in the tumor microenvironment. The use of Lutetium-177 as the radionuclide in this context suggests that it emits beta particles, which can be effective in damaging nearby cancer cells while sparing healthy tissue. Virtual price, please inquire if needed.We can mass produce (kg level),process scaling up, pilot supply,raw material supply, and intermediate production. Our production technology is mature and more cost-effective. Feel free to inquire at any time.	price>
R-M2-9208	89Zr-trastuzumab	89Zr-trastuzumab is a molecular imaging agent used for positron emission tomography (PET) imaging. It consists of the monoclonal antibody trastuzumab, which specifically targets the human epidermal growth factor receptor 2 (HER2), labeled with the radioisotope zirconium-89 (89Zr).This radiopharmaceutical facilitates non-invasive imaging of HER2-positive tumors, aiding in the assessment of the extent and distribution of HER2 expression in various cancers. This imaging can be crucial for treatment planning, monitoring response to therapy, and disease staging, particularly in breast cancer. Virtual price, please inquire if needed.We can mass produce (kg level),process scaling up, pilot supply,raw material supply, and intermediate production. Our production technology is mature and more cost-effective. Feel free to inquire at any time.	price>
R-M2-9209	177Lu-PSMA-617	177Lu-PSMA-617 is an emerging radiopharmaceutical used in targeted radionuclide therapy for prostate cancer. This treatment involves the use of Lutetium-177 (177Lu) combined with PSMA-617, a small molecule that specifically targets prostate-specific membrane antigen (PSMA), a protein highly expressed on prostate cancer cells. Virtual price, please inquire if needed.We can mass produce (kg level),process scaling up, pilot supply,raw material supply, and intermediate production. Our production technology is mature and more cost-effective. Feel free to inquire at any time.	price>
R-M2-9210	177Lu-trastuzumab	77Lu-trastuzumab represents an investigational radiopharmaceutical that combines the monoclonal antibody trastuzumab with Lutetium-177 (177Lu). Trastuzumab, also known as Herceptin, specifically targets the human epidermal growth factor receptor 2 (HER2), which is overexpressed in certain types of cancer, particularly breast cancer. Virtual price, please inquire if needed. We can mass produce (kg level),process scaling up, pilot supply,raw material supply, and intermediate production. Our production technology is mature and more cost-effective. Feel free to inquire at any time.	price>

...